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Abstract
Osmoregulation via maintenance of water and salt homeostasis is a vital process. In the brain, a functional secretin (SCT) and
secretin receptor (SCTR) axis has recently been shown to mediate central actions of angiotensin II (ANGII), including
initiation of water intake and stimulation of vasopressin (VP) expression and release. In this report, we provide evidence that
estrogen-related receptor a (ERRa, NR3B1), a transcription factor mainly involved in metabolism, acts as an upstream
activator of the SCT gene. In vitro studies using mouse hypothalamic cell line N-42 show that ERRa upregulates SCT
promoter and gene expression. More importantly, knockdown of endogenous ERRa abolishes SCT promoter activation in
response to hypertonic and ANGII stimulations. In mouse brain, ERRa coexpresses with SCT in various osmoregulatory brain
regions, including the lamina terminalis and the paraventricular nucleus of the hypothalamus, and its expression is induced
by hyperosmotic and ANGII treatments. Based on our data, we propose that both the upregulation of ERRa and/or the
increased binding of ERRa to the mouse SCT promoter are two possible mechanisms for the elevated SCT expression upon
hyperosmolality and central ANGII stimulation.
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Introduction
Secretin (SCT) is a classical gastrointestinal hormone [1].
Beyond its best known actions on the regulation of bicarbonate,
electrolytes and volume secretion from the pancreatic ductular
epithelial cells, there is a growing body of evidence showing SCT
as a neuropeptide in the CNS [2–5] and as an anti-diuretic
hormone, SCT stimulate the process of renal water reabsorption
in kidney by a VP-independent mechanisms [6]. SCT is found as
a neurosecretory factor released from the neurohypophysis into
circulation upon water deprivation or direct electrical stimulation
of the paraventricular nuclei (PVN) [6,7] to control water
reabsorption in the kidney [5]. Recently, the roles of SCT in the
brain in water regulation were reported, and SCT was found to
have similar functions as the osmoregulatory peptide, angiotensin
II (ANGII) [8]. In these studies, with the aid of the SCTR2/2 and
SCT2/2 mice, it was found that the presence of a functional SCT/
SCTR axis is a prerequisite for some actions of ANGII, including
the upregulation of VP expression in the hypothalamic PVN and
the release of VP protein from posterior pituitary into the
circulation. In addition, SCT itself was found as a dipsogenic
hormone that controls water intake behavior as well as mediates
the dipsogenic effects of ANGII [8].
In specific brain regions, both plasma hypertonicity and
circulating ANGII are able to stimulate the lamina terminalis,
consisting of the subfornical organ (SFO), organum vasculosum of
the lamina terminalis (OVLT) and median preoptic nucleus
(MnPO), which are critical sites for regulating water homeostasis
in rodents [9–14]. Not just that we found SCT and SCTR
expression in these water regulation sites, we found also that SCT
injected into the lateral ventricle of the brain could augment water
drinking behavior, as well as VP expression and VP protein
release. As ANGII via binding to AT1 receptor could stimulate
SCT expression in SFO and OVLT [7], it is therefore possible that
SCT mediates central actions of ANGII partly by controlling the
expression of SCT gene in these osmoregulatory brain regions.
The human and rat SCT promoter have previously been
characterized [15–17], while more recently, small heterodimer
partner (SHP), an orphan nuclear receptor, was identified as
a repressor of the mouse SCT gene by blocking NeuroD-mediated
gene activation in response to bile acids in the mouse duodenum
[18]. Nuclear receptor superfamily is a large group of transcription
factors that are involved in regulation of various physiological
processes, including metabolism, cell growth and differentiation,
development, and homeostasis [19]. A recent study on the
genetically modified mouse model lacking estrogen-related re-
ceptor a (ERRa) revealed its functions in the renin-angiotensin
system (RAS) to regulate renal sodium and potassium homeostasis
[20], indicating potential roles of ERRa in osmoregulation. ERRa
belongs to the NR3B1 subfamily of the orphan nuclear receptors
and is apparently ligand-independent [21]. ERRa is expressed
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with the highest levels in tissues with high energy demands such as
heart, kidney and adipose tissues [22,23]. ERRa recognizes the
estrogen response element (ERE) in target genes as estrogen
receptor (ER) does, but was found to have a higher preference for
the ERE-half site or ERR response element, which is a single half-
site preceded by the three nucleotides TNA [24,25].
In the present study, we investigated a possible mechanism for
the cross-interaction of SCT and ANGII central pathways in
osmoregulation via ERRa. We found that ERRa co-expresses
with SCT in various osmocenters in the CNS, and that its own
expression is regulated by central ANGII and peripheral
hyperosmotic stimulation. Using a hypothalamic cell model,
ERRa was then found to interact specificity with an ERE-half
site in the proximal region of the mouse SCT promoter to control
SCT gene expression. After showing that SCT plays an indispens-
able role in mediating central effects of ANGII (7), the present
study, thus, provide evidence to indicate that ERRa is one of the
mechanisms that connects SCT with central effects of ANGII
and/or plasma osmolality.
Materials and Methods
Constructs and siRNA expressing vectors
The mouse SCT core promoter construct (mSCTP) (from 227
to 2399 bp relative to the start codon) was produced by 1) PCR
amplification using mouse genomic DNA, 2) sequencing, and 3)
subcloning into the pGL2-Basic vector. The mouse ERRa, ERRb
and ERRc expression vectors were constructed using the pcDNA3
vector (Invitrogen, Carlsbad, CA). Site-directed mutants of the
mSCTP promoter were constructed by a three-step mutagenesis
method [26] using the mutagenic primers listed in Table 1. For
gene silencing, two siRNAs specific for the mouse ERRa (siERRa-
S1 and siERRa-S2) were constructed using oligos (pSi-ERRa S1
and pSi-ERRa S2; Table 1) and the pSilencer 4.1-CMV vector
(Hind III/Bam HI sites; Ambion, Austin, TX). The siControl vector
provided by the manufacturer was used as a negative control.
Western blot analysis [18] was used to check the effectiveness of
siRNA in silencing endogenous mouse ERRa. Briefly, N-42 cells
were transfected with 2 mg of the siERRa-S1, siERRa-S2,
siControl or pSilencer vector by GeneJuice (see later for trans-
fection procedures). After 24 h, cells were lysed with RIPA buffer
(50 mM Tris pH 7.4, 0.25% Na-deoxycholate, 1% NP-40,
150 mM NaCl and 1 mM EDTA), and cell lysates were separated
on a 10% SDS-PAGE and transferred to a nitrocellulose
membrane. After incubation with an anti-ERRa antibody (1:500
dilution; Millipore [27]) or GAPDH antibody (loading control,
1:1000; Cell signaling technology) at 4uC overnight, and sub-
sequently by the horseradish peroxidase conjugated secondary
antibody (1:1000 dilution; Santa Cruz Biotechnology) at room
temperature for 1 h, signals were detected by the Western
Lightning plus-ECL Enhanced Chemiluminescence Substrate
(PerkinElmer, Shelton, CT).
Transient transfection and luciferase assay
The mouse hypothalamic cell line, N-42, was purchased from
CELLutions Biosystems Inc (Toronto, Canada). Cells were
cultured in DMEM (31600-034; Invitrogen) supplemented with
4.5 mg/ml D-glucose, 10% FBS (Hyclone, Logan, UT), and the
antibiotics, 100 U/ml penicillin G and 100 mg/ml streptomycin
(Invitrogen) at 37uC with 5% CO2. For transfection, N-42 cells
were seeded onto 6-well plates (35 mm/well; Costar, San Diego,
CA) at a density 2.06105 cells/well. After 2 d, at about 80% cell
confluence, transient transfection was carried out using the
GeneJuice transfection reagent (Novagen, Darmstadt, Germany)
Table 1. Nucleotide sequences of siRNA oligos, EMSA oligos, real-time PCR and mutation analysis (mutated nucleotides are
underlined) primers.
Primer Sequence (59- 30)
siERRa-S1-S GATCCCTTTGCCTTTCCCGGGCCCTTCAAGAGAGGGCCCGGGAAAGGCAAAGGGA
siERRa-S1-AS AGCTTCCCTTTGCCTTTCCCGGGCCCTCTCTTGAAGGGCCCGGGAAAGGCAAAGG
siERRa-S2-S GATCCTGCTGGACCTCTGGCTCTATTCAAGAGATACAGCCAGAGGTCCAGCAGGA
siERRa-S2-AS AGCTTCCTGCTGGACCTCTGGCTGTATCTCTTGAATACAGCCAGAGGTCCAGCAG
GS-ERRa-S GCCCCTGACCTTCCCGG
GS-ERRa-AS CCGGGAAGGTCAGGGC
SCTP-F ACTACTCCTCTAATCTCCCC
SCTP-R GACAAATGCTGCAACTTCAG
GAPDH-F TGTGTCCGTCGTGGATCTGA
GAPDH-R CCTGCTTCACCACCTTCTTGAT
SCT-F GGTGGAGGGCCTCTATCTTC
SCT-R CCAGGCGCTTATAATGGTGT
ERRa-F TTCGGCGACTGCAAGCTC
ERRa-R CACAGCCTCAGCATCTTCAATG
S14-F CAGGACCAAGACCCCTGGA
S14-R ATCTTCATCCCAGAGCGAGC
M1 GAGGGACAGGAGACAGCCGGACGACAG
M2 GGTGGGCGGCCCCAGCCTTCCTGCAAT
M3 TGGGCGGCCTGATTCTTCCTGCAATCA
M4 GGTGCAGCATTTAGTACACCCAGAGCC
doi:10.1371/journal.pone.0039913.t001
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according to the manufacturer’s instruction. For over-expression
studies, the mouse SCT promoter (mSCTP) [15–17] luciferase
construct (2 mg) was co-transfected with different amounts of the
ERRa, ERRb, or ERRc expression vectors (0.5, 1.0, 2.0 mg), and
pCMV-b-gal as an internal control (0.5 mg) per well. For gene
silencing studies, cells were cotransfected with mSCTP luciferase
construct (2 mg), pCMV-b-gal (0.5 mg) and various amounts of
silencing or control vector (1 and 2 mg). Appropriate amount of
the pcDNA3.1 was added so that the total amount of DNA used
per well was the same. Cell extracts were harvested 48 h after
transfection for luciferase and b-galactosidase assays. The pro-
moter activities were measured in at least three independent
experiments each in triplicate assays normalized with b-galacto-
sidase activity. In saline treatment studies, 48 h after transfection,
different concentrations of saline (25, 50, and 100 mM) were
added to the cells for 8 h at 37uC with 5% CO2 for luciferase assay
or RNA isolation.
The SCT expression in N42 cells after saline and ANGII
treatment
Cell was seeded in 6-well plates at a density 2.06105 cells/well.
After 2 d, at which the cell confluence was about 80%, saline
treatment was carried out. Different concentrations of saline were
added to the cells so that the final concentrations of the medium
were 0, 25, 50, and 100 mM. The plate was then incubated at
37uC with 5% CO2 for various time periods (2 h, 4 h or, 8 h)
before harvest. For ANGII treatments, the culture mediums were
replaced by the medium with ANGII in various final concentra-
tion (ranged from 1027 to 10211 M). The cells were collected for
8 h before the RNA isolation and protein extraction. Total RNA
were isolated by TRIzol reagent (Invitrogen). The isolated RNA
was reverse transcribed with oligo-dT primer and Superscript III
reverse-transcriptase (Invitrogen). One-tenth of the first strand
cDNAs was then used as the template in qRT-PCR for measuring
mouse GAPDH, SCT, ERRa, and S14 mRNA levels by the SYBR
Green PCR Master Mix kit (Applied Biosystems, Foster city, CA)
with specific primers (Table 1). The fluorescence signals were
measured in real time during the extension step by the 7300 Real
Time PCR System (Applied Biosystems). The threshold cycle (Ct)
was defined as the fractional cycle number at which the
fluorescence signal reached 10-fold standard deviation of the
baseline (from cycles 2 to 10). The ratio change in the target gene
relative to the GAPDH control gene was determined by the 22DD
Ct method [28]. For western blot analysis, cells were lysed with
RIPA and western blot analysis of ERRawere performed as
described above
MTS Assay
The saline treatments for N-42 cells was performed based on
previous studies [29,30], Cell proliferation assays were performed
using the CellTiter 96 Aqueous One Solution Cell Proliferation
Assay kit (Promega, Madison, MI) according to the manufacturer’s
instructions. N-42 cells were seeded at an optimized density of
2000 cells per well in a 96-well plate and maintained at 37uC with
5% CO2. After 48 h when cell confluence was about 70%,
different concentrations of saline (0, 50, 100, 150, 200, 300,
400 mM) were added for 8 h. After salt treatment, CellTiter 96
Aqueous One Solution Reagent was added for 2 h and
absorbance at 490 nm, which is directly proportional to the
number of living cells in the culture, was measured. Wells with
plain medium with no cells were included as the blank and each
sample was repeated at least 5 times in this study.
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extracts from mouse hypothalamus were prepared as
described before [31]. Oligonucleotides containing the putative
ERE motif (GS-ERRa-S and GS-ERRa-AS; Table 1) were
annealed, end-labeled with [c-32P] ATP by a Ready-To-Go T4-
polynucleotide kinase labeling kit (Amersham Biosciences, Pitts-
burgh, PA) and purified by a Microspin G-25 column (Amersham
Biosciences). Binding reactions were carried out at room
temperature for 15 min in a 20 ml reaction containing 10 mM
Tris (pH 7.5), 50 mM NaCl, 2.5 mM MgCl2, 0.5 mM dithio-
thretiol, 4% glycerol, 2 mg poly(deoxyinosine:deoxycytosine), and
1 rmol radio-labeled probe. Free probes and bound probes were
separated by electrophoresis in a 5% polyacrylamide gel [16,32].
In the supershift assay, 2 mg antibody against ERRa or Ap1 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) were included in the
reaction mix.
Chromatin Immunoprecipitation (ChIP) Assay
ChIP assays were performed as described previously [33]. The
mouse hypothalamus was isolated and nuclear extracts were
prepared as described in [31]. The DNA-protein complexes in N-
42 cells and mouse hypothalamus were cross-linked with 1.42%
formaldehyde and harvested in IP buffer (150 mM NaCl, 50 mM
Tris-HCL (pH 7.5), 5 mM EDTA, 0.5% NP-40, 1% Triton X-
100, 0.5 mM phenylmethylsulfonyl fluoride and 10 mg/ml
leupeptin). To shear the chromatin into DNA fragments, samples
were sonicated (Sonifier 450; Branson Ultrasonics, Danbury, CT)
by 1s-long pulses for 15 times at 50% maximum power output for
2 rounds. The DNA-ERRa complex was immunoprecipitated
with 2 mg rabbit anti-ERRa IgG (Upstate, Millipore, Billerica,
MA) in ice bath followed by the addition of protein A-agarose
(Cruz Biotechnology, Santa Cruz, CA). DNA was isolated in
Chelex-100 slurry (BioRad, Hercules, CA) and the protein was
Figure 1. ERRa upregulates SCT expression in N-42 cells. (A) The 59 upstream sequence of the SCT gene contains a ERE-half site. The
nucleotide sequences (180 bp) upstream of the start codon of the mouse, human and rat SCT gene are shown. The first nucleotide of the start codon
(ATG) is assigned as +1. The consensus sequences of the putative ERE-half site are highlighted in red and underlined. The mutation sites are indicated
by the boxes (B) Effects of over-expressing ERRs in N-42 on the mouse SCT promoter. mSCTP (0.5 mg) and various amounts of the 3 isoforms of ERR/
pcDNA3 (0, 0.5, 1.0 and 2.0 mg) were cotransfected into N-42 cells. Total DNA was adjusted to 2.5 mg by pKS+. *p,0.05; **p,0.001, compared with
mSCTP (0.5 mg). (C) Effects of over-expressing ERRa on the mouse SCT mRNA levels in N-42 cells. The mRNA levels of mouse SCT measured by real-
time PCR were normalized with mouse GAPDH levels. *p,0.05; **p,0.001, compared with control (ERRa – 0 mg). (D–E) Effects of endogenous
silencing of mouse ERRa on (D) mouse SCT promoter and (E) mRNA levels in N-42 cells. The mSCTP (1.0 mg) was co-transfected with various amounts
of siERRa-1 and siERRa-2 (1.0 and 2.0 mg), pSilencer or siControl into N-42 cells. The mRNA levels of mouse SCT measured by real-time PCR were
normalized with mouse GAPDH levels. Data represent the mean6 SEM of three experiments performed in duplicates. *p,0.05; **p,0.001, compared
with mSCTP – 1.0 mg. (B) *p,0.05; **p,0.001, compared with control (pSilencer – 2.0 mg). (F) Western blot analysis of ERRa protein in N-42 cells
transfected with (1) pSilencer (2.0 mg), (2) siERRa-S1, (3) siERRa-S2 and (4) siControl (2.0 mg). The GAPDH western blot was used as the loading control.
(G) Mutation analysis of ERE-half site. Four mutants (M1–M4, 0.5 mg) were cotransfected with pKS+ or ERRa expression vector (2.0 mg). Xp,0.05;
ERRa cotransfected promoter compared with the same construct that transfected with pKS+ (0.5 mg).
doi:10.1371/journal.pone.0039913.g001
Upregulation of SCT by Hypertonicity and ANG II
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39913
removed by proteinase K digestion (0.2 mg/ml). The purified DNA
was used for quantitative real-time PCR (qRT-PCR) with specific
primers (SCTP-F and SCTP-R; Table 1), targeting the mSCTP.
The relative occupancy of the immunoprecipitation factor at the
locus was estimated by 2ˆ (Ctmock– Ctspecific) and normalized with
input DNA, where Ctmock and Ctspecific represent the mean
threshold cycles (Ct) of qRT-PCR (in triplicates) on purified DNA
samples from mock and specific ERRa immunoprecipitation.
Animal handling
All animal treatments were in accordance with the guidelines
established by the Committee on the Use of Live Animals in
Teaching and Research (CULATR, Approval ID 2072-10) of the
University of Hong Kong with the Cap. 340 animal license issued
by the Department of Health of the Hong Kong Government
under the Animals Ordinance. All experiments were carried out
with adult transgenic mice (20–25 g) of N5 generation, which were
kept in a temperature-controlled room with a 12-h light/dark
cycle. Mice were fed ad libitum with standard rodent chow
(no. 5010, Test Diet, IN) and water, unless otherwise stated.
Intracerebroventricular (ICV) incannulation and drug
administration
Mice were anesthetized and surgery was conducted in aseptic
conditions. Procedures for ICV were performed as described
[34,35]. For injections into the lateral ventricle, the coordinates of
Figure 2. Effects of saline and ANGII treatments on SCT promoter activity and gene expression in N-42 cells. (A) Osmolality of culture
medium after treatment of different concentrations of saline (0, 50, 100, 200, 300, 400 mM) for 8 h in N-42 cells. (B) Percentage of cells surviving after
saline treatments with medium of various concentrations (0, 50, 100, 150, 200, 300, 400 mM) for 8 h in N-42 cells. (C) Cells were transfected with
mSCTP (2.0 mg) for 2 d and treated with various saline concentrations (25, 50, 100 mM) for different times (2, 4, 8 h) or ANGII (10210 to 1027 M) for
8 h. Data represent the mean 6 SEM of three experiments performed in triplicates. (D and E) Cells were treated with various saline concentrations
(25, 50, 100 mM) for different times (2, 4, 8 h) and RNA was extracted afterwards. The mRNA levels of mouse SCT (D) and S14 (E) were normalized with
mouse GAPDH levels. Data represent the mean 6 SEM of three experiments performed in duplicates.*p,0.05; **p,0.001, compared with the
respective control.
doi:10.1371/journal.pone.0039913.g002
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cannula implantation were determined according to the mouse
brain atlas [36]. The cannula (11-mm-long, 21-gauge stainless
steel tubing) was stereotaxically placed such that the tip was
0.5 mm caudal to bregma, 1.0 mm lateral to midline, and 2.0 mm
below the dura. The placement was confirmed by injection of
a dye. Three days were allowed for recovery before ICV injection.
Central injections were done using PE-10 tubing attached to an
injector and a 10-ml Hamilton syringe. Artificial cerebrospinal
fluid (ACSF; according to Alzet protocol, 2 or 5 ml), ANGII
(100 ng/2 ml; 002-12; Phoenix Pharmaceuticals, Belmont, CA), or
saline (0.25 or 0.50 M/5 ml) were injected into the lateral
ventricle.
Water deprivation and saline drinking followed by Laser-
capture microdissection (LCM) and qRT-PCR
To induce hypertonic serum in mice, normal drinking water
was either removed for 1 d or replaced with 2% saline for 5 d.
Treated and control mice were then sacrificed and their brains
were collected. For ICV studies, 1 h after the ICV injection,
similarly, brains of treated and control mice were isolated. For
whole brain studies, total RNA was extracted by the TriPure
isolation reagent (Roche Molecular Biochemicals, Basel, Switzer-
land). For study of the specific brain areas, the brains were
embedded in OCT compound (Sarura Finetek, Torrance, CA)
and stored at 220uC. The frozen brain was then sectioned (8-mm
thick) using a cryostat microtome (Jung CM3000, Lieca Micro-
systems, Leitz, Germany) and mounted on plain slices. Brain
sections at the level of the lamina terminalis and PVN were stained
with hematoxylin and eosin and imaged on the PixCell IIe Laser
Capture Microdissection System (Arcturus, Sunnyvale, CA).
Target cells were located according to the mouse brain atlas and
were captured on CapSure HS LCM Caps (Arcturus). RNA of
captured cells was prepared using the PicoPure RNA Isolation Kit
Figure 3. Effects of ERRa silencing on the SCT promoter in response to hyperosmotic shock. (A) Cells were treated with various saline
concentrations (25, 50, 100 mM) for different times (2, 4, 8 h) or ANGII (10211 to 1027 M) for 8 h, and RNA was extracted afterwards. The mRNA levels
of mouse ERRa were normalized with mouse GAPDH levels. Data represent the mean 6 SEM of three experiments performed in duplicates.*p,0.05;
**p,0.001, compared with the respective control. (B) Western blot analysis of ERRa protein in N-42 cells after saline (upper) and ANGII (10211 to
1029 M). (C) Effect of saline and ANGII treatment on ERE-half site mutants. Cells were transfected with mSCTP, M2 or M3 (2.0 mg) for 2 d and treated
with saline (100 mM) for different times or ANGII (1028 M) for 8 h. Data represent the mean 6 SEM of three experiments performed in triplicates.
*p,0.05, compared with the control promoter without treatment. (D) N-42 cells were transfected with mSCTP (2.0 mg) and either pSilencer (Control)
(2.0 mg) or pSi-mERRa-S1 (2.0 mg). After 2 d, cells were subject to treatement with saline-added medium of different concentrations (25, 50, 100 mM)
or ANGII (10210 to 1027 M) for 8 h. Data represent the mean 6 SEM of three experiments performed in triplicates.*p,0.05; **p,0.001, compared
with the control transfected with pSilencer without treatment. #p,0.05, compared with the control transfected with pSi-mERRa-S1 without
treatment.
doi:10.1371/journal.pone.0039913.g003
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(Arcturus). The isolated RNA was reverse transcribed and real-
time PCR were performed as described above.
Immunohistochemical (IHC) staining
IHC staining was performed as described [6,35]. Brains isolated
from mice were fixed in 3.7% formalin, embedded in paraffin, and
sectioned (7 mm). Paraffin sections were dewaxed and rehydrated
in graded ethanol. Endogenous peroxidase activity was blocked by
3% hydrogen peroxide in methanol. Microwave antigen retrieval
was performed with citric acid buffer at pH 6.0 for 10 min,
followed by blocking of non-immunological binding with 5%
normal goat serum for 2 h. Sections were then incubated with
rabbit anti-ERRa IgG (1:500 dilution; Millipore) overnight at 4uC.
Figure 4. Effects of water deprivation, saline dinking and central ANGII administration on mouse ERRa expressions in mouse brain.
Mice were water deprived, provided with hypertonic saline (2%) for 1 or 5 d, or centrally injected with ANGII peptide. The mRNA levels of mouse ERRa
in (A) the whole mouse brain or (C) the isolated osmosentitive brain regions SFO, OVLT, MnPO and PVN, were measured by real-time PCR were
normalized with mouse GAPDH levels. Data are expressed as the mean 6 SEM (n= 10/group). *p,0.05; **p,0.001, compared with control. (B)
Immunohistochemical staining showing ERRa immunoreactivities in the SFO, MnPO, OVLT and PVN of the WT mouse brain. Negative control was
done by using 16 PBS instead of the primary anti-ERRa antibody. Bars, 6 mm.
doi:10.1371/journal.pone.0039913.g004
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Primary antibody was replaced by 16PBS in the negative controls.
Immunoreactive signals were obtained by the Vectastain ABC
Elite kit (Vector Laboratories, Burlingame, CA) in light brown
color using 16 DAB substrate (Roche Diagnostics, Shanghai,
China) and counterstained with hematoxylin (Zymed Laborato-
ries, San Francisco, CA).
Figure 5. Effect of saline and ANGII on the binding of ERRa to the mouse SCT promoter. (A) ChIP assay showing the relative occupancy of
the immunoprecipitated ERRa at the mouse SCT promoter in N42 cells after saline and ANGII treatment for 8 h in N-42 cells. Data was calculated
using the equation: 2ˆ (Ctmock–Ctspecific) and normalized with Input, which was defined as 1.00. A mock immunoprecipitation using rabbit anti-IgG and
without using antibody were carried out as negative control. Data represent the mean 6 SEM of three experiments.*p,0.05; **p,0.001, compared
with the control. (B) EMSA using the ERE-half site as the oligo. Left: Nuclear extract of mouse hypothalamus (10 mg), pcDNA (control), and in vitro
translated ERRa protein were pre-incubated with the oligo for 15 minutes at room temperature. Arrows indicate specific protein-DNA complexes that
contain ERRa (Complex I) and unknown protein (complex II). Middle: Hypothalamic nuclear extract of control or water deprived or saline-drank mice
were used (n = 4/group) in EMSA. Right: Supershift assay of ERRa proteins. Antibodies (2 mg) specific for ERRa and AP1 (Santa Cruz) proteins were pre-
incubated with the nuclear extract (10 mg) for 20 min at room temperature. Arrows indicate specific protein–DNA complexes that contain ERRa
(Complex I), non-specific complex (Complexes II) and ERRa supershift (SS). (C) ChIP assay showing the in vivo binding of ERRa on mouse SCT
promoter in mouse hypothalamus after water deprivation and saline treatment (left) and ICV-ANGII injection in mice (1 and 4 h) (right).
doi:10.1371/journal.pone.0039913.g005
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Statistical analysis
All data are shown as means 6 standard error SEM. The
deviations between groups were analyzed using the computer
software PRISM (version 3.0, GraphPad Software, La Jolla, CA).
Unpaired t-test was performed when only two groups were under
consideration, whereas data from more than two groups were
analyzed by one-way ANOVA, followed by Dunnett’s test.
Results
ERRa upregulates SCT gene in the hypothalamic N-42 cell
line
In view of a recent study revealing a potential function of ERRa
in the renin-angiotensin system (RAS) for osmoregulation [9] and
the presence of an ERE-half site in the proximal region of the
mouse (from 2149 to 2144 bp, relative to the start codon), rat
and human SCT promoters (Fig. 1A), we initially investigated the
in vitro function of ERRs to control the mouse SCT gene in a mouse
hypothalamic N-42 cell-line. In this study, each of the three
isoforms of ERR (a, b and c) was overexpressed with the mouse
SCT promoter-luciferase construct. As shown in Fig. 1B, the SCT
promoter was significantly (1.92-fold and 2.18-fold for 1.0 and
2.0 mg of ERRa, respectively) activated only by ERRa, which is
a constitutive activator [37,38], whereas overexpression of neither
ERRb nor ERRc showed an activation effect on mouse SCT
promoter. Consistent with this observation, endogenous SCT
mRNA levels were significantly elevated (1.63-fold and 2.15-fold
for 1.0 and 2.0 mg of ERRa, respectively) when ERRa was
overexpressed in N-42 cells (Fig. 1C). In order to confirm further
a functional role of ERRa, two siRNA vectors specific for
targeting the mouse ERRa were designed. Silencing of the
endogenous ERRa in N-42 cells, by using either of the silencing
vectors (S1 or S2), resulted in considerable drops in the mouse SCT
promoter activities (S1: 39.7% and 63.2% decrease; S2: 26.4%
and 51.6% decrease) (Fig. 1D), and also in the endogenous SCT
transcript levels (S1: 38.9% and 57.2% decrease; S2: 42.4%
decrease for 2 mg) (Fig. 1E). The siRNA were functional in
lowering endogenous ERRa expression as indicated by Western
blotting (Fig. 1F), in which ERRa protein levels were substantially
reduced. These findings suggested that ERRa is responsible for the
upregulation of mouse SCT expression in the hypothalamic cells.
The direct relationship between the ERE-half site and the ERRa
mediated activation of mSCTP were confirmed by mutation
analysis (Fig. 1G). The promoter activities were increased with
ERRa cotransfection in the mutants that not related to ERE-half
site (M1 1.8 fold and M4 1.9 fold when compare to pKS+ control),
whereas the mutation of ERE-half site can severely decrease
ERRa-mediated activation effects (only 1.08 fold for M2 and 1.13
fold for M3). The data clearly suggested that the ERE-half site is
the critical motif for the ERRa responsiveness in mSCTP.
ERRa is a mediator of the hypertonicity- and ANGII-
induced upregulation of SCT
After showing ERRa as an activator of the SCT gene, our next
task was to study if ERRa was involved also in the osmoregulatory
pathway. We have previously revealed that SCT expression was
upregulated in the mouse hypothalamus in response to water
deprivation and saline drinking [8]. To examine the effect of
hypertonic shock on the mouse SCT gene, N-42 cells were treated
with different concentrations of hypertonic salt treatment (25, 50
and 100 mM) for 2, 4 and 8 h (Fig. 2C) as in a previous study [29].
Before the treatment, the toxicity of hypertonic saline to the N42
cells was tested by MTS assay. The corresponding osmolality in
different concentration of NaCl was shown in Fig. 2A. The MTS
assay (Fig. 2B) suggested that the lethal concentration 50 of NaCl
is around 150 mM. Therefore, the maximum concentration of
NaCl that used in the N42 cells treatment is 100 mM. Hypertonic
treatment of cells led to time- and dose-dependent increases in
SCT promoter activities (Fig. 2C), in which the 8-h treatment with
100 mM saline resulted in the strongest induction (2.45-fold).
Likewise, hypertonic saline treatment could stimulate endogenous
SCT expression in a similar pattern (Fig. 2D). In this study, the
mouse house-keeping gene S14 was used as a control which
expression was not affected by hypertonic saline under all the
conditions tested (Fig. 2E). Consistently, ANGII peptide dose-
dependently (10211 to 1027 M, 8 h treatment) activated mouse
SCT promoter (Fig. 2C) as well as endogenous SCT mRNA levels
(Fig. 2D). ANGII at the concentration 10210 M was found to
produce the greatest stimulation (2.89 folds). Again, ANGII
treatment was unable to change the expression of the mouse S14
housekeeping gene, as a control.
Similar to their effects on SCT, both hypertonic shock and
ANGII could also stimulate mouse ERRa mRNA expression
(Fig. 3A) as well as the ERRa protein level (Fig. 3B) in this
hypothalamic cell model. When siERRa construct (pSi-mERRa-
S1) was employed to silence endogenous ERRa, consistent with
findings in Fig. 2D, the effects of both hypertonic saline and
ANGII treatment were almost completely abolished (Figure 3D).
This upregulation of mouse SCT expression is dependent on the
ERE-half site. As shown in Fig. 3C, the mutation of this motif (M2
and M3) cause a large and significant reduction in the response to
the saline and ANGII treatment. Taken together, our data show
the potential function of ERRa in mediating stimulatory effects of
hypertonic saline and ANGII on SCT expression.
In vivo functions of ERRa in osmoregulation in the mouse
brains
To study the in vivo functions of ERRa to upregulate SCT in
response to hypertonic treatment and ANGII, we initially
investigated expression levels of ERRa in mouse brain in response
to hyperosmotic stimuli and central ANGII administration. We
found that ERRa transcript levels in the mouse cerebrum were
significantly elevated after water deprivation, saline drinking or
ICV-ANGII in mice (Fig. 4A). We have previously shown the
localization of SCT transcript and protein in various osmoregu-
latory sites, including the SFO, OVLT and MnPO, and that SCT
transcript levels were significantly enhanced upon water depriva-
tion and saline drinking [8]. By IHC stainings, ERRa proteins
were also found in sites collectively known as lamina terminalis
and PVN of the mouse brain (Fig. 4B). By LCM-coupled with
qRT-PCR, expression changes of ERRa in these brain regions
were studied (Fig. 4C). ERRa transcript levels in the PVN, SFO,
MnPO and OVLT were significantly augmented after water
deprivation and saline drinking (Fig. 4C). One hour after ICV-
ANGII injection, ERRa levels in the PVN and OVLT were
elevated while its levels in the SFO and MnPO were unchanged
(Fig. 4C) The expression changes of ERRa could therefore
activate SCT expression in these areas as shown in our in vitro
studies in N42 cells.
In vitro and in vivo binding of ERRa to the ERE-half site of
the mouse SCT promoter
Despite the presence of an ERE-half site in the mouse SCT
promoter (Fig. 1A), there was no previous report showing the
functional interaction of ERRa with this motif. In the present
study, using EMSA and ChIP assay, we seek to investigate the
binding of ERRa to the SCT promoter ERE-half site in N-42 cells
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and mouse hypothalamus (Fig. 5). In the ChIP assay (Fig. 5A), we
observed no PCR signal from the negative controls including the
no antibody, and anti-rabbit IgG control. The controls show
neither nonspecific precipitations nor PCR contamination in this
assay. Positive PCR signals are found in the samples treated with
ERRa antibody. This suggested the in vivo binding of ERRa with
the mouse SCT promoter. The ChIP assay coupled to qRT-PCR,
more importantly, showed that both saline and ANGII treatments
were able to increase the ERRa binding. EMSA using mouse
hypothalamic nuclear extract showed the presence of two DNA-
protein complexes (I and II) (Fig. 5B left). To confirm the identity
of these complexes, we performed EMSA by incubating the same
probe with in vitro translated mouse ERRa proteins, which was
found to form a complex with a size similar to complex I. In the
ERRa supershift assay, the intensity of complex I was decreased
and a supershift band was observed (Fig. 5B right). No supershift
band can be observed in the control (AP1 antibody). This
supershift assays suggests that complex I contains ERRa protein.
To show changes in binding of ERRa, we have used nuclear
extracts prepared from the hypothalamus of mice under water
deprivation and saline drinking, and we found that the intensities
of complex I were increased after these treatments (Fig. 5B
middle).
Consistent with results in these in vitro studies (Fig. 5A), ChIP
assay showed the in vivo occupancy of the SCT ERE-half site with
ERRa was greatly induced by water deprivation, saline drinking,
and 4 h after the ICV-ANGII administration (5.83-fold) in the
mouse hypothalamus (Fig. 5C). In summary, the above findings
indicate the increased expression and binding of ERRa with the
SCT ERE-half site in the mouse hypothalamus is a mechanism for
the elevated SCT expressions in response to hyperosmolality and
central ANGII stimulation.
Discussion
By reviewing the 59 sequence (1800 bp upstream of the
transcriptional start site) of the mouse SCT gene, an ERE-half
site, a putative binding site for the orphan nuclear receptor ERR,
is present at 2149 bp (Fig. 1A). In the past, there were several
studies revealing essential regulatory sequence motifs within the
human and rat SCT promoter [15,16,39], and recently, the mouse
SCT gene has been shown to be regulated by Sp1/Sp3 interacting
with two GC-boxes (at 2125 and 2158) and NeuroD binding
with an E-box motif (at 2167), [17,18]. In the present study, we
provided evidences that ERRa interacting with the ERE-half site
in the mouse SCT promoter is implicated for mediating central
effects of ANGII.
There have been studies suggesting estrogen plays functional
roles in fluid regulation in rodent and human [40–42]. ERRs are
closely related to ERs, with which they share almost identical DBD
(68% amino acid homology) [43–45]. In view of its close
relationship with the ER, and that ERRa is often shown to act
synergistically with ERa [25], ERRa is hypothesized as a possible
candidate that participates in osmoregulation. In the present study,
ERRa expression was revealed to be responsive to ANGII
stimulation in the hypothalamic cells, and in the lamina terminalis
and PVN of mouse brain. This is similar to previous study on ERa
that water deprivation led to increased ERa expression in the SFO
[46]. ERa is localized extensively in the osmosensitive neurons in
the lamina terminalis and the SON, whereas ERb is prominently
expressed in the VP magnocellular neurons of rat hypothalamus
[47,48]. Likewise, using immunohistochemical staining and real-
time PCR, the present study showed that ERRa proteins and
transcripts were localized in the lamina terminalis and PVN,
which are important brain regions for the control of VP secretion
and drinking behavior.
In agreement with its expression patterns in high energy
demand tissues, ERRa is generally recognized as a transcription
factor that regulates expression of genes involved in bioenergetics
[49,50], as a biomarker for several human cancers [51–53], bone
homeostasis [54], as well as in cell proliferation and migration
[55,56]. The ERRa knockout mice are viable, fertile and display
no gross anatomical alterations, but have reduced body weight
with less peripheral fat mass [57]. More recently, a physiological
study of ERRa deficient (ERRa2/2) mice have identified the
potential of ERRa in regulating blood pressure and water
homeostasis, by controlling renal sodium and potassium homeo-
stasis and the RAS [20]. In summary, phenotypic analysis revealed
that the ERRa2/2 mice have reduced water intake, urine volume,
and increased Na+ in blood. These indicate that ERRa is
dipsogenic and diuretic. Also, ERRa knockout mice are deficient
in renal Na+/K+ handling with a mechanism that favor Na+
retention, leading to the increased blood Na+ and thus increased
water reabsorption and decreased urine volume. Using genome-
wide ChIP-on-ChIP analysis and expression profile comparison of
ERRa2/2 and WT mice, the study also identified a number of
target genes regulated by ERRa in kidney. Some of these are
genes involved in water regulation, including the RAS genes (Ren1,
Agt, Ace2), VP receptor (Avpr1a, Avpr2), and tonicity-responsive
element (TonE) binding protein (TonEBP). Our findings show that
ANGII upregulates ERRa in the lamina terminalis and PVN in the
brain; while Tremblay et al. suggested that ERRa could down-
regulate RAS genes in kidney, which might work as a negative
feedback control [20]. Compatible with our study that shows
ANGII can stimulate ERRa, and thus SCT and VP expression; VP
receptor genes in kidney were found to be downregulated in the
ERRa2/2 mice [20], indicating that ERRa is responsible for
intensifying the renal actions of VP. In summary, this report
suggests new functions of ERRa in osmoregulation by regulating
SCT’s action in the brain. In view of an indispensable role of SCT
and SCTR axis in mediating functions of ANGII in the central
nervous system, this study not only confirmed, but also filled in the
missing gap between ANGII and SCT in this newly discovered
osmoregulatory pathway.
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